The soluble metal-binding domain of the copper transporter ATP7B binds and detoxifies cisplatin

Biochem J. 2009 Apr 1;419(1):51-6, 3 p following 56. doi: 10.1042/BJ20081359.

Abstract

Wilson disease ATPase (ATP7B) has been implicated in the resistance of cancer cells to cisplatin. Using a simple in vivo assay in bacterial culture, in the present study we demonstrate that ATP7B can confer resistance to cisplatin by sequestering the drug in its N-terminal metal-binding domain without active drug extrusion from the cell. Expression of a protein fragment containing four N-terminal MBRs (metal-binding repeats) of ATP7B (MBR1-4) protects cells from the toxic effects of cisplatin. One MBR1-4 molecule binds up to three cisplatin molecules at the copper-binding sites in the MBRs. The findings of the present study suggest that suppressing enzymatic activity of ATP7B may not be an effective way of combating cisplatin resistance. Rather, the efforts should be directed at preventing cisplatin binding to the protein.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphatases / chemistry
  • Adenosine Triphosphatases / genetics
  • Adenosine Triphosphatases / metabolism*
  • Binding Sites
  • Cation Transport Proteins / chemistry
  • Cation Transport Proteins / genetics
  • Cation Transport Proteins / metabolism*
  • Cisplatin / metabolism*
  • Cisplatin / pharmacology
  • Copper-Transporting ATPases
  • Escherichia coli / drug effects
  • Escherichia coli / genetics
  • Escherichia coli / metabolism
  • Hepatolenticular Degeneration / metabolism
  • Microscopy, Interference
  • Protein Binding
  • Protein Structure, Tertiary

Substances

  • Cation Transport Proteins
  • Adenosine Triphosphatases
  • Copper-Transporting ATPases
  • Cisplatin